Leukoreduction on the agenda at US public health meeting in July:
This article was originally published in Clinica
Executive Summary
US public health officials have scheduled a public workshop on July 20 in Bethesda, Maryland, to discuss the latest developments in leukoreduction. Topics will include observed clinical adverse events and manufacturing failures, the FDA's current thinking about quality control tests and standards for the procedure, and new scientific developments in filtration, including developing a way to remove prions from blood. The workshop will be sponsored jointly by the FDA, the US National Heart Lung and Blood Institute and the Office of Public Health and Science in the US Department of Health and Human Services. For more information, or to register, contact Rhonda Dawson at the FDA's biologics centre, on tel: +1 301 827 3514; email: [email protected]
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.